Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRKR)

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

PR Newswire January 5, 2021

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results

PR Newswire November 9, 2020

Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020

PR Newswire November 2, 2020

Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PR Newswire September 17, 2020

Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results

PR Newswire August 10, 2020

Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

PR Newswire June 30, 2020

Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia

PR Newswire June 23, 2020

Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

PR Newswire May 29, 2020

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

PR Newswire May 13, 2020

Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

PR Newswire May 11, 2020

Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020

PR Newswire May 4, 2020

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

PR Newswire April 29, 2020

Marker Therapeutics Reports Full Year 2019 Operating and Financial Results

PR Newswire March 12, 2020

Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million

PR Newswire March 2, 2020

Marker Therapeutics to Present at Two Upcoming Investor Conferences

PR Newswire February 18, 2020

Marker Therapeutics Announces Update to its Clinical Program in AML

PR Newswire February 11, 2020

Marker Therapeutics to Present at Two Upcoming Investor Conferences

PR Newswire November 25, 2019

Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results

PR Newswire November 12, 2019

Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019

PR Newswire November 11, 2019

Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

PR Newswire August 15, 2019